Opinion|Videos|July 1, 2024
Treatments Approved for Treatment of Spinal Muscular Atrophy
Key opinion leaders (KOLs) examine the mechanisms of action and other pertinent information regarding FDA-approved treatments for spinal muscular atrophy (SMA), sharing their perspectives on these therapies with a particular focus on the various modes of administration.
Advertisement
- Please review mechanism of action and other details for treatments that are FDA approved for SMA.
- Nusinersen, Onasemnogene abeparvovec, Risdiplam
- Based on the pathophysiology of SMA, do you expect mechanism of action to impact disease pathology differently?
How do you feel about mode of administration?
How do you discuss the progressive nature of SMA with your adult patients?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
International Committee Publishes 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis
2
New Study Finds Link Between Gut Hormone GLP-1 and NMOSD Symptoms, Paving Way for Targeted Treatments
3
RELIEV-CM Pilot Study Data Further Supports ShiraTronics’ Neuromodulation Device to Treat Chronic Migraine
4
Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition
5